Previous 10 | Next 10 |
Editors Note: This story was originally published on June 13, but due to some technical problems we had to reset the website and as a result, the story got erased. This is the same story but republished. Biotechnology is always a dicey business to create, run, and make p...
Biotechnology is always a dicey business to create, run, and make profitable. Psychedelics add a difficulty factor of 10 to that equation. Currently, there are many psychedelic companies still working their compound through clinical trials—with no actual product to ma...
Shares of mental health biopharma Atai Life Sciences N.V. have fallen some two-thirds from their June 2021 IPO pricing as the biotech market continues to crater. The company’s approach of identifying (in many instances psychedelic) compounds that have been tested in previous hu...
ATAI has a large portfolio of drugs, mainly psychedelics, that can be used to treat mental health conditions when other options have failed. There is ample room for new drug developments in this space, given that R&D for new drug developments has been declining. Success depend...
When it comes to unusual options activity, Reddit, Twitter, and even stock market chat rooms seem to love this data. There are unusual options activity scanners that you can use to find stocks with irregular volume in their options chains. There are also websites like ours that scour throug...
atai Life Sciences N.V. (ATAI) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Greg Weaver – Chief Financial Officer Florian Brand – Chief Executive Officer Srini Rao – Chief Scientific Officer Conference Call Participants Charles Duncan ...
German clinical-stage biopharmaceutical company Atai Life Sciences (NASDAQ:ATAI) is trading higher on Monday in reaction to the company’s 1Q 2022 results. The U.K.-based biotech COMPASS Pathways (CMPS), in which it holds an ownership stake, is also rising in solidarity. Atai&...
An earnings and business update video call today for Atai Life Sciences (NASDAQ-ATAI), a clinical-stage biopharmaceutical company that acquires, incubates and develops innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders, featured ...
ATAI Life Sciences press release (NASDAQ:ATAI): Q1 GAAP EPS of -$0.24 in-line. Cash, cash equivalents and short-term investments of $335M. “We made great progress in the first quarter on our mission to achieve clinically meaningful behavioral change in people living with mental health ...
– Strong execution across atai’s three strategic pillars: rapid acting pharmacological intervention, ongoing digital support and biomarker-driven precision mental health – Key milestones include first subject dosed in Phase 1 KUR-101, launch of drug discovery engi...
News, Short Squeeze, Breakout and More Instantly...
ATAI Life Sciences N.V. Company Name:
ATAI Stock Symbol:
NASDAQ Market:
ATAI Life Sciences N.V. Website:
Alcohol use disorder is a disorder characterized by an inability to stop or control one’s drinking despite adverse health, occupational or social consequences. Conventional treatments include medication, behavioral therapy, and support groups. Even with these treatments, however, many ind...
Psychedelics such as DMT, LSD and psilocybin have demonstrated promise in the treatment of affective symptoms of a range of disorders. These drugs work by inducing an altered state of consciousness , which includes intensified perceptions and emotions, which have been associated with therapeutic...